Overview

Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma

Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to find out if Afatinib can help treat participants with advanced cSCC.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute
Collaborator:
Boehringer Ingelheim
Treatments:
Afatinib